E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Endoscopically confirmed gastroesophageal reflux disease (GERD), Grade A-D according to Los Angeles (LA) classification |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10018203 |
E.1.2 | Term | GERD |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the superiority of Soraprazan 20 mg qd compared to Soraprazan 10 mg qd in healing rates over 4 and 8 weeks of treatment in patients suffering from GERD, Grade A-D |
|
E.2.2 | Secondary objectives of the trial |
Endoscopically confirmed healing and symptom relief of Soraprazan 20 mg qd and Soraprazan 10 mg qd compared to Esomeprazole 40 mg qd after 4 and 8 weeks of treatment. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
· Written informed consent by the patient for study participation, prior to protocol specific procedures · Outpatients being 18 - 65 years of age · Endoscopically confirmed gastroesophageal reflux esophagitis (Grade A-D classification, determined via the Los Angeles classification system, including photo documentation) · Frequent episodes of acid-related symptoms defined as on at least 4 days during the last week prior to inclusion into the study
|
|
E.4 | Principal exclusion criteria |
Signs, indicating other gastrointestinal diseases · Zollinger-Ellison syndrome or other gastric hypersecretory condition · Previous acid-lowering surgery or other surgery of the esophagus and/or upper gastrointestinal tract (exception: polypectomy and cholecystectomy) · On initial endoscopy, presence of obstructive esophageal strictures, Schatzki’s ring, esophageal diverticula, esophageal varices, achalasia or Barrett’s esophagus with known high-grade dysplasia or longer than 3 cm · Symptomatic GERD without any endoscopic finding · Acute peptic ulcer and/or ulcer complications · Pyloric stenosis · Symptoms of irritable bowel syndrome that dominate the clinical picture · Inflammatory bowel diseases
Other concomitant diseases · Myocardial infarction within the previous 3 months prior to inclusion into the study or any unstable or severe heart disease (e.g. clinically overt heart failure (NYHA III-IV), unstable angina pectoris, severe uncontrolled arterial hypertension) · Subjects with percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) within the last 3 months prior to inclusion into the study · History of drug-induced Torsade de Pointes, or presence of a familial long QT syndrome · History or evidence of clinically relevant arrhythmias (atrial fibrillation, frequent and complex extrasystoles, ventricular tachycardia, ventricular pre-excitation syndromes) · Relevant serum hypokalemia (< 3,5 mmol/L) · Severe or unstable pulmonary or endocrine disease; clinically significant renal or hepatic disease or dysfunction; hematologic disorder; any other clinically significant medical condition that could increase the risk to the study participant · Malignant disease of any kind during the previous 5 years except for successfully treated skin (basal or squamous cell) cancer · Tendency to react allergically to drugs, especially with known hypersensitivity to one of the compounds of the study medication (except isolated allergy to penicillin or related antibiotics) · Alcohol, drug or medication abuse within the past year · Clinically relevant abnormal vital signs suggesting an underlying disease and requiring further clinical evaluation · Severe psychiatric or neurologic disorders
Special restrictions for female patients · Pregnant or nursing female patients · Female patients of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as - oral, injectable, or implantable contraceptives, - intrauterine contraceptive devices, - or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Please note that female patients who are surgically sterilized / hysterectomized, or post-menopausal > 2 years are not considered as being of childbearing potential.
Previous medication · Intake of proton pump inhibitors (PPIs) during the previous 14 days prior to the start of the study · H2-receptor antagonists or prokinetics during the last 7 days before the start of the study · Any medication for the purpose of the eradication of H. pylori during the last 28 days before the start of the study · Systemic glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2-inhibitors (>5 days on demand but not more than 3 consecutive days) during the last 28 days before the start of the study; except regular intake of acetylsalicylic acid in dosages up to 150 mg/d
Concomitant medication · PPIs (except investigational medicinal product), H2-receptor antagonists, prokinetics, sucralfate, antacids, bismuth preparations or other substances, which may have an influence on the relief of acid-related symptoms · Systemic glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2-inhibitors (>5 days on demand but not more than 3 consecutive days) except regular intake of acetylsalicylic acid in dosages up to 150 mg/d · Ketoconazole or other drugs with pH-dependent absorption · Drugs with a small therapeutical window, i.e. anti-coagulants, anti-epileptics, theophylline, digitalis glycosides, and anti-arrhythmics · PPIs in combination with antibiotics for the purpose of the eradication of H. pylori · Onset of psychotropic medication (e.g. benzodiazepines)
Others · Patients who are expected to be non-compliant and/or not co-operative · Participation in the treatment phase of any other clinical study within the last 30 days prior to the start of the study · Patients who have participated already in this study · Patients who are employees at the investigational site, relatives or spouse of the investigator · Any donation of germ cells, blood, organs, or bone marrow during the course of the study · Patients who are not contractually capable |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Endoscopically proven healing of Soraprazan 20 mg qd and Soraprazan 10 mg qd after 4 weeks and 8 weeks of treatment in patients suffering from GERD, Grade A-D |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 0 |